RossCDonehowerMD
Oncology • Lutherville, MDProfessor of Oncology, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Medical Oncology/Hematogy Fellowship Training Program, Director, Division of Medical Oncology
Dr. Donehower is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10803 Falls Road
Pavilion Iii Ste 1500
Lutherville, MD 21093Phone+1 410-583-2970Fax+1 410-583-2980
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1980
Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
University of Minnesota Medical SchoolClass of 1974
Certifications & Licensure
MD State Medical License 1979 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Excellence in Teaching Award American Society of Clinical Oncology, 2017
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Join now to see all
Clinical Trials
- Penclomedine in Treating Patients With Advanced Solid Tumors Start of enrollment: 1996 Dec 01
- UCN-01 in Treating Patients With Advanced Cancer Start of enrollment: 1998 Jun 01
- MG98 in Treating Patients With Advanced Solid Tumors Start of enrollment: 1999 Feb 22
- Join now to see all
Publications & Presentations
PubMed
- 4435 citationsMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne Bartlett
Science. 2017-07-28 - 51 citationsCombination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.Nilofer S. Azad, Anthony B. El-Khoueiry, Jun Yin, Ann L. Oberg, Patrick J. Flynn
Oncotarget. 2017-02-06 - 906 citationsPD-1 Blockade in Tumors with Mismatch-Repair Deficiency.Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling
The New England Journal of Medicine. 2015-06-25
Press Mentions
Johns Hopkins University Hematology Oncology FellowshipApril 30th, 2017
Grant Support
- Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–2007
- Phase I Trial/Pharmacokinetis Of Tas 103 Solid In TumorsNational Center For Research Resources2000–2002
- Trial Of Bryostatin 1 Given As Continuous Infusion In Cancer PatientsNational Center For Research Resources1998–2002
- Phase I Dose Escalation, Safety, Tolerability Of Tas 103National Center For Research Resources1997–2002
- Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2000
- Phase II Pharm Study--Flavopiradol (Nsc 649890) In Colorectal CancerNational Center For Research Resources1999
- Phase II Trials Of New Anticancer AgentsNational Cancer Institute1994–1998
- Phase I Clinical Trial Of Anticancer AgentsNational Cancer Institute1995–1997
- Pharmacokinetic Studies Of Anticancer AgentstheDivision Of Cancer Treatment1994–1995
- Navelbine Bioavailability In Solid Tumors And LymphomaNational Center For Research Resources1992–1993
- 7u85 Mesylate Intravenous Administration Daily For Five DaysNational Center For Research Resources1992–1993
- Phase I And Pharmacokinetic Studies Of Anticancer AgentsDivision Of Cancer Treatment1990–1993
- Bioavailability Of Piritrexim Isethionate In Advanced Cancer PatientsNational Center For Research Resources1992
Professional Memberships
- Fellow
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ross-donehower
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
